16 October 2019
Visiongain has launched a new pharma report ‘’Mouth Ulcers Treatment Market Report 2020-2030’’ by Formulation (Gel, Mouthwash, Ointment, Spray, Other Formulations), Drug Class (Analgesics & Corticosteroids, Antihistamine, Antimicrobial, Other Drug Classes), Indication (Aphthous Stomatitis, Oral Lichen Planus, Other Indications), and Geography.
The global Mouth Ulcers Treatment market is anticipated to grow at a lucrative CAGR of 4.1% and anticipated to reach USD 1,550 Million by 2030.
Mouth ulcers are painful sores that form on the mouth's soft tissue, including lips, cheek, tongue, and gums. Mouth ulcers may make eating, drinking, and brushing teeth difficult for some patients. Most of the ulcers in the mouth are benign, recurrent and get cleansed on their own within 1-2 weeks.
People, however, have a highly casual approach to mouth ulcers that can adversely affect market growth. There is a lack of awareness about the fact that they can lead to cancer if not treated during the early stages. Nevertheless, healthcare professionals are carrying out active initiatives and tests to raise awareness and avoid harmful effects caused by mouth ulcers. This trend is anticipated to boost the growth of global mouth ulcers market over the forecast period.
Also factors such as awareness of modern treatments, rising geriatric population, availability of rapid healing and easy to use products are anticipated to fuel the growth of the mouth ulcer treatment market.
Based on formulation, the global mouth ulcer treatment market is segmented into ointment, gel, mouthwash, spray, among other formulations. In the year 2018, gels held the majority of the global market share owing to rapid healing formulas, easy availability, and fast anti-inflammatory& anti-swelling properties. They also have anesthetic properties, which temporarily relieve mouth sores or ulcers from unbearable pain.
Asia Pacific region holds the majority of market share and is expected to experience the highest growth in terms of CAGR over the forecast period owing to supportive government initiatives and increasing awareness about oral hygiene. The region, on account of growing healthcare infrastructure and a large population base, is anticipated to open growth avenues for upcoming market players in the region.
Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations and launching new products in order to strengthen their position in the global mouth ulcer treatment market. Companies are also increasing their R&D, distribution, and management facilities in order to expand their business and to hold a competitive edge in the market.
The comprehensive market report features companies such as 3M, Bristol Myers Squibb Company, Church & Dwight Co. Inc., Blistex Inc., Dr.Reddy’s Laboratories, Colgate- Palmolive Company, GlaxoSmithKline Plc., ECR Pharmaceuticals, Pfizer Inc., and Taro Pharmaceutical Industries Ltd. among other prominent players. Also the research study offers market estimation and forecast for the period ranging 2020–2030 for global markets such as North America, Latin America, Western Europe, Eastern Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Nordic, Benelux, Russia, Poland, India, Japan, China, Australia, ASEAN, GCC, South Africa and North Africa.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Rising preference for personalised medicine in developed as well developing economies coupled with increasing investment by biotechnological and pharmaceutical companies for drug discovery is expected to increase RNA analysis/transcriptomics market concentration over the forecast period. In order to increase the reliability and success rate of the drug production process.
30 November 2020
The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.
26 November 2020
Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.
26 November 2020
Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.